Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ketoconazole followed by octreotide for Cushing's disease
NL-OMON36055Recruiting
- Sponsor
- Erasmus MC Rotterdam
- Start
- Dec 2011
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Open-label trial of ketoconazole, octreotide and cabergoline in Corticotropin adenoma (ACTHoma) (2 arms), sponsored by Erasmus MC Rotterdam. Primary endpoint: Urinary free cortisol excretion. Started Dec 2011; status: recruiting.
02
Drugs
ketoconazoleoctreotidecabergoline
03
Conditions
Corticotropin adenoma (ACTHoma)
Beyond the preview
Go deeper on NL-OMON36055.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON36055.